Science

ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 25/10/2026, 07:20:24 UTC.

Briefings

A study published in Nature on October 25, 2026, reports on ctDNA clearance and outcomes for resectable lung cancer from the NeoCOAST-2 trial. The study found that complete ctDNA clearance was associated with improved overall survival in patients with resectable lung cancer, though the specific survival benefit was not statistically significant in the primary analysis. The findings suggest that detecting and clearing circulating tumor DNA may be a valuable biomarker for prognosis in this patient population.

Key points

• Complete ctDNA clearance was associated with improved overall survival in patients with resectable lung cancer from the NeoCOAST-2 trial.
• The primary analysis did not show a statistically significant survival benefit for complete ctDNA clearance compared to incomplete clearance.

Context

This study analyzes data from the NeoCOAST-2 trial, a clinical trial investigating ctDNA clearance in resectable lung cancer. The findings contribute to understanding prognostic biomarkers in lung cancer management.

Limitations

The primary analysis did not show a statistically significant survival benefit for complete ctDNA clearance compared to incomplete clearance. The study is based on data from a single trial, and the specific survival benefit was not statistically significant in the primary analysis.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 25/10/2026, 07:21:32 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicxfbpuoikuhtv2btpscjgc7tz6l42q3f2bsqwysu5mcnprwsubc4